Delwinds Insurance, a Houston SPAC, has completed its business combination with Foxo Technologies. As a result, the company has been renamed and is now based in Minneapolis.
Foxo is developing proprietary saliva-based epigenetic biomarkers with a plan to create simper, smoother, non-invasive underwriting of life insurance. Currently, underwriting involves lengthy timelines and invasive blood and urine specimen requirements.
Epigenetic biomarkers are chemical modifications, called DNA methylation that alter gene expression from external stimuli such as lifestyle and environment. The company plans to use automated machine learning to identify patterns of epigenetic biomarkers that correlate to health and wellness (e.g tobacco use, hypertension, alcohol abuse etc).
Foxo started in 2019. The company is projecting its first revenues in 2023 with positive EBITDA during the following year. The transaction values Foxo at $300 million and leaves it with $194 million in cash to fund its growth.
Delwinds went public in December 2020 in a $200 million Initial Public Offering. It planned to target businesses in insurance technology so the deal for Foxo (announced in February 2022) definitely met that criteria. Delwinds had 18 months from its IPO to complete a deal, otherwise it would be wound up and the cash returned to investors. In May, it received a 3-month extension to Sept 15.